自发性脑出血是指脑实质内非创伤性血管破裂出血，其危害主要来自颅内血肿的占位效应及血肿周 围脑组织继发性损害。随着外科手术技术的发展，自发性脑出血的治疗从传统的开颅手术向微创手术转 变，已成为最具潜力的技术。微创穿刺血肿清除术治疗脑出血方便快捷、创伤小、安全有效且费用低廉，其 中利用生化酶使血肿液化是该技术的核心之一，可安全快速清除血肿，有效改善患者预后。本文就微创穿 刺血肿清除术联合血肿液化剂治疗脑出血的相关研究进展进行综述。

Spontaneous intracerebral hemorrhage (ICH) refers to non-traumatic vascular rupture and bleeding within the brain parenchyma. Its harm primarily stems from the space-occupying effect of the intracranial hematoma and secondary damage to the surrounding brain tissue. With the advancement of surgical techniques, the treatment of spontaneous ICH has shifted from traditional craniotomy to minimally invasive surgery (MIS), becoming one of the most promising technologies. MIS is fast, convenient, less traumatic, safe, effective, and cost-effective. One of the core aspects of this technique is the use of biochemical enzymes to liquefy the hematoma, allowing for safe and rapid removal of the hematoma and effectively improving patient outcomes. This article reviews the research progress on the treatment of ICH with MIS combined with hematoma liquefaction agents.